Top Markets
#1 DogBull DogBull +104.58%
#2 Siacoin Siacoin +51.37%
#3 ADO Protocol ADO Protocol +46.38%
#4 MarsCoin MarsCoin +44.35%
#5 UnifAI Network UnifAI Network +42.92%
#6 Magma Finance Magma Finance +28.97%
#7 Useless Coin Useless Coin +26.04%
#8 Ontology Gas Ontology Gas +20.36%
#9 Cash Cat Cash Cat +17.48%
#10 Apertum Apertum +14.63%
Coin of the day
DogBull DogBull
設定
言語
日本
通貨
USD
テーマ
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
株式のランク #13891
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
株価
$12.45
時価総額
$451.84M
変化（1日）
-1.39%
変化（1年）
-
国
US
取引 Evommune, Inc. (EVMN)

カテゴリー

Healthcare
Evommune, Inc.（EVMN）の配当利回りの履歴
Evommune, Inc.（銘柄コード: EVMN）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Evommune, Inc.（EVMN）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.48%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH